ABSTRACT
The number of patients awaiting lung transplantation has steadily increased over the past two decades, as improvements in outcomes have made lung transplantation an accepted therapy for end-stage lung disease. Despite a steady increase in the potential recipient pool, the number of deceased-donor lung transplants performed has not increased accordingly due to a lack of donor lungs, despite liberalizing the standard donor criteria and considering older and sometimes more marginal donors (1-3). This donor-to-supply mismatch is even more severe in those who require bilateral lung transplantation because of suppurative lung disease, such as cystic fibrosis. With this disparity in mind, our group developed living-lobar lung transplantation as an alternative to deceased-donor lung transplantation (4,5).
